All In Biotech

Drug Trial Radar · NCT01893138

Autologous Muscle Derived Cells for Female Urinary Sphincter Repair

A Double-blind, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR With Placebo in Female Subjects With Stress Urinary Incontinence

Last checked: Nov 19, 2026Latest source record: Jan 5, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 311 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

311

Actual

Start

Nov 21, 2013

Primary completion

Nov 1, 2019

Study completion Nov 10, 2020

Sponsor

Lead sponsor
Cook MyoSiteIndustry
Sponsor type
Industry
First posted
Jul 8, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized, double-blind, placebo-controlled, multicenter, confirmatory study will evaluate the efficacy and safety of Cook MyoSite Incorporated Autologous Muscle-Derived Cells (generic name Iltamiocel) compared to a placebo (vehicle) control dose in the treatment of stress urinary incontinence (SUI) in adult female patients.

Conditions

  • Stress Urinary Incontinence

Interventions

  • PlaceboOther

    Placebo control is the vehicle solution used for the study product.

  • IltamiocelBiological

    AMDC is the study product (autologous muscle-derived cells). The generic name is iltamiocel. Single intraurethral injection of 150 x 10\^6 cells.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Participants With ≥ 50% Reduction in Stress Incontinence Episode Frequency From Baseline to 12 Months Post-treatment; as Assessed by 3 Day DiaryTime frame: Baseline and 12 months

Locations

29 sites in 3 countries. Site status is shown where the registry gives one.

  • Mayo Clinic Arizona Phoenix Campus

    Phoenix, Arizona

  • The American Association of Female Pelvic Medicine Specialists

    Agoura Hills, California

  • Ronald Reagan UCLA Medical Center

    Los Angeles, California

  • Stanford University

    Stanford, California

  • Cleveland Clinic Florida

    Weston, Florida

  • Emory University

    Atlanta, Georgia

  • NorthShore University HealthSystem

    Skokie, Illinois

  • IU Health Physicians Urogynecology

    Indianapolis, Indiana

  • Female Pelvic Medicine & Urogynecology Institute of Michigan

    Grand Rapids, Michigan

  • Mercy Health Saint Mary's Campus

    Grand Rapids, Michigan

  • William Beaumont Hospital

    Royal Oak, Michigan

  • NYU Urology Associates

    New York, New York

  • Premier Medical Group of the Hudson Valley PC

    Poughkeepsie, New York

  • Montefiore Medical Center

    The Bronx, New York

  • McKay Urology

    Charlotte, North Carolina

  • The Carl and Edyth Lindner Center for Research and Education at The Christ Hospital

    Cincinnati, Ohio

  • Cleveland Clinic

    Cleveland, Ohio

  • University of Oklahoma Health Sciences Center

    Oklahoma City, Oklahoma

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania

  • Medical University of South Carolina

    Charleston, South Carolina

  • Greenville Health System

    Greenville, South Carolina

  • Sanford Female Pelvic Medicine and Reconstructive Surgery Clinic

    Sioux Falls, South Dakota

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Methodist Urology Associates

    Houston, Texas

  • Inova Fairfax Hospital

    Falls Church, Virginia

  • Benaroya Research Institute at Virginia Mason

    Seattle, Washington

  • University Hospital Leuven

    Leuven, Belgium

  • Universitätsklinikum Essen

    Essen, Germany

  • Praxisklinik Urologie Rhein-Ruhr (PUR/R)

    Mülheim, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.